NCT03083171 is a Phase 1 clinical trial of Endotoxin in Healthy Volunteers, sponsored by Adrenomed AG.

Who is sponsoring NCT03083171?

NCT03083171 is sponsored by Adrenomed AG.

What drugs are being tested in NCT03083171?

Interventions in NCT03083171: Endotoxin, Placebo, Adrecizumab.

What condition does NCT03083171 study?

NCT03083171 studies Healthy Volunteers.

Is NCT03083171 still recruiting?

NCT03083171 is currently completed. Last updated 1 February 2021.

Last reviewed 2021-02-01 · How we verify

NCT03083171

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adrecizumab-LPS Study

Completed Phase 1 Last updated 1 February 2021

What this trial tests

Phase 1 trial testing Endotoxin in Healthy Volunteers in 24 participants. Completed in 24 May 2017.

Timeline

4 January 2017

Primary endpoint
24 May 2017

24 May 2017

Quick facts

Lead sponsor	Adrenomed AG
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	4 January 2017
Primary completion	24 May 2017
Estimated completion	24 May 2017
Sites	1 location across Netherlands

Drugs / interventions tested

Endotoxin — full drug profile →
Placebo
Adrecizumab — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Adrenomed AG

Who can join

Adults 18 to 35, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this randomized, double-blind, placebo-controlled study, either a single dose of Adrecizumab (0.5, 2.0 or 8.0 mg/kg) or placebo will be administrated to 24 healthy male volunteers during experimental endotoxemia.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System.
Bálint L, Nelson-Maney NP, Tian Y, Serafin SD, et al · · 2023 · cited 32× · PMID 37104556 · DOI 10.1161/circresaha.123.321673
Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis.
Kharga K, Kumar L, Patel SKS. · · 2023 · cited 25× · PMID 36979744 · DOI 10.3390/biomedicines11030765
Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.
Vázquez R, Riveiro ME, Berenguer-Daizé C, O'Kane A, et al · · 2020 · cited 25× · PMID 33489885 · DOI 10.3389/fonc.2020.589218

Verify or expand the search:

Other trials of Endotoxin

Trials testing the same drug.

NCT05363527 — Aging and Reward System Response to Inflammation and Anxiety Study · Phase 1 · completed
NCT04527185 — Effect of Endotoxin on Alcohol Consumption · Phase 2 · completed
NCT04310423 — An Inflammatory Challenge Using Endotoxin · Phase 2 · completed
NCT03848715 — Sleep and Healthy Aging Research on Depression for Younger Women · Phase 1 · completed
NCT03256760 — Sleep and Healthy Aging Research for Depression (SHARE-D) Study · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Adrenomed AG trials

Trials by the same sponsor.

NCT03085758 — Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03083171 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adrenomed AG
Last refreshed: 1 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03083171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing